Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Bacterial Infections: early-phase trial registry
3 of 19 indexed Bacterial Infections trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #902 of 28,707 conditions by registered trial count.
19 US clinical trials · 3 currently recruiting · #902 of 28,707 conditions by registered trial count
Bacterial Infections: 19 US clinical trials tracked, 3 recruiting.
Bacterial Infections is the subject of 19 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most active sponsor is Qpex Biopharma, running 3 of these trials.
Enrollment posture brief
Registry condition bacterial-infections
OPEN 3 | RECR 16% | LATE 3 | EARLY 14 | RANK #902 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Influenza, Human (16% recruiting · 19 trials)
Bacterial Infections lists 3 open slots (16% of 19 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Bacterial Infections on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Bacterial Infections is recruiting below its size-band peers.
3 of 19 indexed trials (15.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Bacterial Infections research.
Qpex Biopharma accounts for 3 of 19 trials (15.8%). 16 distinct sponsors appear on at least one study for this condition label.
-
Most Bacterial Infections trials plan to enrol fewer than 100 people.
Median target enrolment is 40 among the 18 trials that report a genuine target (sentinel values excluded). 14 of those (77.8%) plan for fewer than 100 participants.
-
Bacterial Infections research is mostly interventional.
17 interventional and 2 observational studies make up this index (89.5% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
19 total, page 1 of 1
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics
NCT05645107
A Study to Investigate Safety and Pharmacokinetics of Intravenous Cefiderocol/Xeruborbactam in Participants With Renal Impairment
Qpex Biopharma
NCT07104162
[18F]Fluoropropyl-Trimethoprim ([18F]F-TMP) PET/CT Imaging to Evaluate Biodistribution and Kinetics in Human Subjects
University of Pennsylvania
NCT04263792
Dose-finding, Pharmacokinetics, and Safety of VABOMERE in Pediatric Subjects With Bacterial Infections
Rempex (a wholly owned subsidiary of Melinta Therapeutics, LLC)
NCT02687906
Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections
Forest Laboratories
NCT00423657
Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)
Bayer
NCT02066402
Study of the Safety and Pharmacokinetics of KSP-1007 Alone and Coadministered With Meropenem in Healthy Subjects
Sumitovant Biopharma
NCT05226923
Study to Evaluate Safety, Tolerability, and Pharmacokinetics of XNW4107 Alone or in Combination With Imipenem/Cilastatin
Evopoint Biosciences
NCT04482569
OR PathTrac (Tracking Intra-operative Bacterial Transmission)
Sundara Reddy
NCT03605498
P1 Single and Multiple Ascending Dose (SAD/MAD) Study of IV QPX7728 Alone and Combined With QPX2014 in NHV
Qpex Biopharma
NCT04380207
A Pilot of Pediatric/Adult Study of Gene Expression Profiling and Clinical Characterization of Phototoxicity
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NCT00353158
A Phase 1 TP-271 Oral PK Multiple Ascending Dose Study
Tetraphase Pharmaceuticals
NCT03450187
Blood Volume Assessment in COVID-19 and Bacterial Sepsis
NYU Langone Health
NCT04517695
Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects
Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company)
NCT01702649
PK & Safety Study of Xeruborbactam Oral Prodrug Combined With Ceftibuten in Participants With Renal Impairment
Qpex Biopharma
NCT06157242
Safety and Pharmacokinetics of Clindamycin in Pediatric Subjects With BMI ≥ 85th Percentile
Phillip Brian Smith
NCT01744730
Evaluation of Atuna Racemosa Toxicity
Mayo Clinic
NCT00318344
A Study of Azithromycin in HIV-Infected Patients
Pfizer
NCT00002344
Phase I Study of the Clinical Pharmacology of Azithromycin in Buffy Coat of HIV-Infected Subjects.
Pfizer
NCT00002139
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 14 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Bacterial Infections records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Bacterial Infections trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Bacterial Infections page
19 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Bacterial Infections trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Qpex Biopharma sponsors the most Bacterial Infections trials on record, review their full trial history before evaluating a specific study. See Qpex Biopharma's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Bacterial Infections condition card totals 19 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.